THE EFFICACY AND SAFETY OF POTASSIUM CLAVULANATE/ AMOXICILLIN (CLAVAMOX®D) RY SYRUP IN CHILDREN WITH OTITIS MEDIA

  • SUGITA RINYA
    Sugita Otorhinolaryngology Clinic
  • YAMANAKA NOBORU
    Department of Otolaryngology-Head & Neck Surgery, Wakayama Medical University
  • KUDO FUMIYO
    Department of Nutrition, Chiba College of Health Science
  • ITO RIE
    Development & Medical Affairs Division, GlaxosmithKline K.K.
  • KAWAI MOTOR
    Development & Medical Affairs Division, GlaxosmithKline K.K.
  • OHWAKI ICHIRO
    Development & Medical Affairs Division, GlaxosmithKline K.K.
  • ASANO SATOSHI
    Development & Medical Affairs Division, GlaxosmithKline K.K.
  • NAGATA TSUTAE
    Development & Medical Affairs Division, GlaxosmithKline K.K.

Bibliographic Information

Other Title
  • 小児中耳炎患者を対象としたクラブラン酸カリウム・アモキシシリン配合剤 (クラバモックス®) 小児用ドライシロップの有効性, 安全性の検討

Description

To evaluate the efficacy and safety of CLAVAMOX® dry syrup (potassium clavulanate/amoxicillin) in children with otitis media, we conducted a postmarketing surveillance from February to September 2006. The analysis was made on the basis of 470 survey sheets collected from 127 medical institutions, of which we investigated 455 cases for safety, and 433 cases for efficacy.<BR>The efficacy was 95.2% in the 433 subjects eligible for the efficacy analysis. The clinical improvement rates for major symptoms (otalgia, otorrhea, flare reaction of drum membrane and fever) were 95% or more.The efficacies for the three major offending bacteria of otitis media (Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis) were between 94.6% and 100%. The efficacies for penicillin-resistant Streptococcus pneumoniae (PRSP) and penicillin intermediate resistant Streptococcus pneumoniae (PISP) were 95% or more.<BR>Adverse drug reactions (ADRs) were reported in 106 (23.3%) of the 455 subjects eligible for safety analysis. The major ADRs were diarrhea, of which incident was 22.6% (103 of 455). TheseADRs were observed at a higher rate in younger age patients.<BR>Most of the diarrhea cases were non-serious, reversible. on discontinuation or continuation of the drug. No clinically important serious diarrhea cases such as pseudomembranous colitis or dehydration were observed.<BR>Our surveillance results demonstrated that CLAVAMOX® dry syrup had excellent efficacy and clinically manageable safety in children with otitis media. These findings indicated that this medicine was clinically-useful in children with otitis media.

Journal

Details 詳細情報について

  • CRID
    1390001205494974592
  • NII Article ID
    130004396068
  • DOI
    10.11553/antibiotics1968b.60.221
  • COI
    1:STN:280:DC%2BD2snosFCntg%3D%3D
  • ISSN
    21865477
    03682781
  • PubMed
    18018419
  • Text Lang
    ja
  • Article Type
    journal article
  • Data Source
    • JaLC
    • PubMed
    • CiNii Articles
  • Abstract License Flag
    Disallowed

Report a problem

Back to top